Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Borderline Resectable Pancreatic Adenocarcinoma: early-phase trial registry
3 of 8 indexed Borderline Resectable Pancreatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Borderline Resectable Pancreatic Adenocarcinoma: 8 US clinical trials tracked, 3 recruiting.
Borderline Resectable Pancreatic Adenocarcinoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition borderline-resectable-pancreatic-adenocarcinoma
OPEN 3 | RECR 38% | LATE 0 | EARLY 8 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Borderline Resectable Pancreatic Adenocarcinoma lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Borderline Resectable Pancreatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Borderline Resectable Pancreatic Adenocarcinoma is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Borderline Resectable Pancreatic Adenocarcinoma research.
M.D. Anderson Cancer Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Borderline Resectable Pancreatic Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.
-
Borderline Resectable Pancreatic Adenocarcinoma research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT05825066
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT05688215
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics
NCT06673017
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
NCT04481204
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Candel Therapeutics
NCT02446093
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
University of Utah
NCT04106856
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
NCT04669197
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04940286
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Borderline Resectable Pancreatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Borderline Resectable Pancreatic Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Borderline Resectable Pancreatic Adenocarcinoma page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Borderline Resectable Pancreatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Borderline Resectable Pancreatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Borderline Resectable Pancreatic Adenocarcinoma condition card totals 8 registered trials; most-linked intervention Gemcitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.